Abeona Therapeutics Inc. (ABEO) Receives Buy Rating from Jefferies Group LLC
Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating reaffirmed by analysts at Jefferies Group LLC in a note issued to investors on Wednesday. They presently have a $28.00 price target on the biopharmaceutical company’s stock. Jefferies Group LLC’s target price suggests a potential upside of 73.37% from the company’s previous close.
Other equities analysts also recently issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Abeona Therapeutics in a research report on Monday, September 18th. Citigroup Inc. assumed coverage on Abeona Therapeutics in a research report on Tuesday, October 10th. They issued a “buy” rating and a $32.00 target price on the stock. Maxim Group set a $17.00 target price on Abeona Therapeutics and gave the company a “buy” rating in a research report on Wednesday, August 16th. BidaskClub downgraded Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 27th. Finally, Zacks Investment Research downgraded Abeona Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the stock. Abeona Therapeutics has a consensus rating of “Buy” and a consensus target price of $25.30.
Shares of Abeona Therapeutics (NASDAQ ABEO) opened at $16.15 on Wednesday. Abeona Therapeutics has a twelve month low of $4.05 and a twelve month high of $22.75.
Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. The company had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.22 million. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. analysts expect that Abeona Therapeutics will post -0.7 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Abeona Therapeutics Inc. (ABEO) Receives Buy Rating from Jefferies Group LLC” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/22/abeona-therapeutics-inc-abeo-receives-buy-rating-from-jefferies-group-llc.html.
Institutional investors have recently modified their holdings of the stock. State of Wisconsin Investment Board purchased a new position in Abeona Therapeutics in the 2nd quarter worth approximately $122,000. Rhumbline Advisers purchased a new position in Abeona Therapeutics in the 2nd quarter worth approximately $190,000. Wells Fargo & Company MN lifted its stake in Abeona Therapeutics by 3,421.8% in the 3rd quarter. Wells Fargo & Company MN now owns 35,218 shares of the biopharmaceutical company’s stock worth $600,000 after purchasing an additional 34,218 shares in the last quarter. Family Management Corp lifted its stake in Abeona Therapeutics by 50.0% in the 3rd quarter. Family Management Corp now owns 36,000 shares of the biopharmaceutical company’s stock worth $614,000 after purchasing an additional 12,000 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. purchased a new position in Abeona Therapeutics in the 2nd quarter worth approximately $264,000. 36.34% of the stock is currently owned by hedge funds and other institutional investors.
Abeona Therapeutics Company Profile
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).
Receive News & Stock Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related stocks with our FREE daily email newsletter.